Denosumbab May Hold Key For an Amgen Recovery?
By Trista Morrison
Monday, February 4, 2008
Although still trading near its 52-week low, Amgen Inc. got a boost at the end of January thanks to better than expected earnings and new data showing that osteoporosis drug denosumab outperformed Fosamax (alendronate, Merck & Co. Inc.) in a Phase III trial. (BioWorld Financial Watch)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.